Management Guidelines for Mycoplasma genitalium Positive Test
For a patient testing positive for Mycoplasma genitalium, initiate treatment with azithromycin 500 mg orally on day 1, followed by 250 mg once daily for days 2-5, which achieves 93-99% cure rates for macrolide-susceptible infections. 1
Diagnostic Confirmation and Co-Infection Testing
Before initiating therapy, confirm the diagnosis using nucleic acid amplification testing (NAAT) and simultaneously test for gonorrhea and chlamydia, as co-infections are common and require different treatment approaches. 1
- When available, perform macrolide resistance testing at the time of initial diagnosis to guide appropriate antibiotic selection. 2
- Confirm objective signs of infection (mucopurulent discharge, ≥5 WBCs per oil immersion field on urethral Gram stain, or ≥10 WBCs per high-power field on first-void urine microscopy) before treating. 2
First-Line Treatment Algorithm
For Macrolide-Susceptible or Unknown Resistance Status:
- Azithromycin 500 mg orally on day 1, then 250 mg orally once daily for days 2-5 (cure rate 93-99%). 1
- This extended azithromycin regimen is superior to single-dose azithromycin 1g, which has declining efficacy (dropping from 85.3% before 2009 to 67% after 2009) and increases macrolide resistance development. 1
- Avoid single-dose azithromycin 1g due to resistance concerns. 1
For Macrolide-Resistant Infections (Second-Line):
- Moxifloxacin 400 mg orally once daily for 7 days for uncomplicated infections. 2, 3
- For complicated infections (PID, epididymitis), extend moxifloxacin to 14 days. 3
Alternative Approach When Resistance Testing Unavailable:
The Korean guidelines recommend a two-step approach for treatment failures: doxycycline or minocycline 100 mg orally twice daily for 7 days, followed by azithromycin 1g on day 1, then 500 mg once daily for 3 days. 4
Critical Patient Instructions
- Patients must abstain from sexual intercourse for 7 days after completing single-dose therapy or until completion of multi-day regimens. 1
- Dispense medications on-site when possible and directly observe the first dose to maximize compliance. 1
- All sexual partners require evaluation and treatment, even if asymptomatic, to prevent reinfection. 1
Follow-Up Requirements
- Patients should return for evaluation if symptoms persist or recur after treatment completion, as this indicates treatment failure requiring resistance testing and alternative therapy. 1
- Test-of-cure should be performed at least 3 weeks after therapy completion, as testing earlier may yield false-positive results with NAAT due to detection of non-viable organisms. 1
- Repeat testing at 3-6 months is recommended due to high reinfection rates. 1
Management of Treatment Failures
When patients fail initial macrolide-guided treatment (occurring in approximately 32% of cases), consider the following: 5
- If macrolide-resistant, use moxifloxacin 400 mg daily for 7 days. 2
- For persistent infections after both azithromycin and moxifloxacin failure, consider pristinamycin 1g four times daily for 10 days (cure rate ~75%) or doxycycline/minocycline 100 mg twice daily for 14 days (cure rate 40-70%). 3
- Verify treatment compliance and possible reexposure to untreated partners before escalating therapy. 6
Key Clinical Pitfalls to Avoid
- Do not use doxycycline alone as first-line therapy for confirmed M. genitalium, as it has only a 30-40% cure rate. 1, 3
- Avoid repeated courses of moxifloxacin despite previous failures, as fluoroquinolone resistance is increasing. 5
- Do not screen asymptomatic individuals without M. genitalium exposure history, as this leads to unnecessary antibiotic use and promotes antimicrobial resistance. 2, 7
- Testing is not recommended in asymptomatic pregnant patients without exposure history. 8